Ischemic Stroke Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Market Impact by DelveInsight | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Inc., NoNO, Pharming

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ischemic Stroke pipeline constitutes 50+ key companies continuously working towards developing 55+ Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Ischemic Stroke Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ischemic Stroke Market.

 

The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Ischemic Stroke Pipeline Report:

Companies across the globe are diligently working toward developing novel Ischemic Stroke treatment therapies with a considerable amount of success over the years. 

Ischemic Stroke companies working in the treatment market are TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others, are developing therapies for the Ischemic Stroke treatment 

Emerging Ischemic Stroke therapies in the different phases of clinical trials are- Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others are expected to have a significant impact on the Ischemic Stroke market in the coming years.   

In January 2024, Aruna Bio has revealed intentions to commence a Phase I/II clinical trial of AB126 for treating acute ischemic stroke by the first half of 2024. This decision follows the clearance of the company’s investigational new drug (IND) application by the US Food and Drug Administration (FDA) for its lead program, AB126. This milestone represents the first IND approval for Aruna Bio’s platform. 

 

Ischemic Stroke Overview

An ischemic stroke, also known as a brain attack, happens when a blood artery in the brain breaks or when something stops the blood supply to a portion of the brain. Either way, certain brain regions suffer harm or even die. A stroke can result in death, long-term incapacity, or permanent brain damage.

 

Get a Free Sample PDF Report to know more about Ischemic Stroke Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

 

Emerging Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

Microlyse: TargED Biopharmaceuticals

ST-01: Saillant Therapeutics

Elezanumab: AbbVie

RNS60: Revalesio Corporation

BIIB131: Biogen

Glenzocimab: Acticor Biotech

3K3A-APC: ZZ Biotech

Nelonemdaz: GNT Pharma

MultiStem: Athersys, Inc.

Glenzocimab: Acticor Biotech

Elezanumab: AbbVie

LT3001: Lumosa Therapeutics

AVLX-144: Avilex Pharma

 

Ischemic Stroke Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Oral

Intravenous

Subcutaneous

Parenteral

Topical

 

Ischemic Stroke Molecule Type

Ischemic Stroke Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

 

Ischemic Stroke Pipeline Therapeutics Assessment

Ischemic Stroke Assessment by Product Type

Ischemic Stroke By Stage and Product Type

Ischemic Stroke Assessment by Route of Administration

Ischemic Stroke By Stage and Route of Administration

Ischemic Stroke Assessment by Molecule Type

Ischemic Stroke by Stage and Molecule Type

 

DelveInsight’s Ischemic Stroke Report covers around 55+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

 

Further Ischemic Stroke product details are provided in the report. Download the Ischemic Stroke pipeline report to learn more about the emerging Ischemic Stroke therapies

 

Some of the key companies in the Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Ischemic Stroke are – Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Athersys, Inc., Tarveda Therapeutics, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Avilex Pharma, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

 

Ischemic Stroke Pipeline Analysis:

The Ischemic Stroke pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.

Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Ischemic Stroke drugs and therapies

 

Ischemic Stroke Pipeline Market Drivers

Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Ischemic Stroke Market.

 

Ischemic Stroke Pipeline Market Barriers

However, challenges associated with the clinical research, challenges with the diagnosis of AIS and other factors are creating obstacles in the Ischemic Stroke Market growth.

 

Scope of Ischemic Stroke Pipeline Drug Insight    

Coverage: Global

Key Ischemic Stroke Companies: TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others

Key Ischemic Stroke Therapies: Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others

Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies

Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and Ischemic Stroke market barriers 

 

Request for Sample PDF Report for Ischemic Stroke Pipeline Assessment and clinical trials

 

Table of Contents

1. Ischemic Stroke Report Introduction

2. Ischemic Stroke Executive Summary

3. Ischemic Stroke Overview

4. Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment

5. Ischemic Stroke Pipeline Therapeutics

6. Ischemic Stroke Late Stage Products (Phase II/III)

7. Ischemic Stroke Mid Stage Products (Phase II)

8. Ischemic Stroke Early Stage Products (Phase I)

9. Ischemic Stroke Preclinical Stage Products

10. Ischemic Stroke Therapeutics Assessment

11. Ischemic Stroke Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ischemic Stroke Key Companies

14. Ischemic Stroke Key Products

15. Ischemic Stroke Unmet Needs

16 . Ischemic Stroke Market Drivers and Barriers

17. Ischemic Stroke Future Perspectives and Conclusion

18. Ischemic Stroke Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×